Zobrazeno 1 - 10
of 15
pro vyhledávání: ''
Autor:
Michael B. Sporn, Di Zhang, Samir J. Ibrahim, Karen T. Liby, Ana S. Leal, Pamela A. Marshall, Carl E. Wagner, Pritika H. Shahani, San Raban, Peter W. Jurutka, Sarah Carapellucci, Jaskaran S. Bhogal
Publikováno v:
Cancer Prevention Research. 12:211-224
Rexinoids, selective ligands for retinoid X receptors (RXR), have shown promise in preventing many types of cancer. However, the limited efficacy and undesirable lipidemic side-effects of the only clinically approved rexinoid, bexarotene, drive the s
Autor:
Takatsugu Okegawa, Shuta Tomida, Suguru Hamada, Kikuo Nutahara, Hidetoshi Hayashi, Kazuko Sakai, Masato Terashima, Kazuto Nishio, Yu Nakamura, Yosuke Togashi, Yoshihiko Fujita, Eri Banno, Marco A. De Velasco, Hirokazu Nakahara
Publikováno v:
Molecular Cancer Therapeutics. 15:1988-1997
The prognosis for patients with advanced esophageal or head-and-neck squamous cell carcinoma (ESCC or HNSCC) remains poor, and the identification of additional oncogenes and their inhibitors is needed. In this study, we evaluated the sensitivities of
Autor:
Randall J. Kimple, Johan Lantto, Zachary S. Morris, David M. Francis, Craig R. Hullett, Eric A. Armstrong, Chunrong Li, Paul M. Harari, Lauryn R. Werner, Adam D. Swick, Michael Kragh, Shyhmin Huang
Publikováno v:
Clinical Cancer Research. 22:633-643
Purpose: Aberrant regulation of the EGF receptor family (EGFR, HER2, HER3, HER4) contributes to tumorigenesis and metastasis in epithelial cancers. Pan-HER represents a novel molecular targeted therapeutic composed of a mixture of six monoclonal anti
Autor:
Félix Bonilla, Cristina Peña, Belén Pérez-Sacristán, F. Granado-Lorencio, Gemma Domínguez, Beatriz Gil-Calderón, Jesús Espinosa Romero, Encarnación Donoso, Coral San Millán, Beatriz Soldevilla, Marta Compte, Paloma Martín
Publikováno v:
Digital.CSIC. Repositorio Institucional del CSIC
instname
instname
[Background]: The acquired resistance to chemotherapy represents the major limitation in the treatment of cancer. New strategies to solve this failure and improve patients' outcomes are necessary. The cancer preventive effect of β-cryptoxanthin has
Autor:
Kami J. Maddocks, Mondana H. Ghias, Soumyasri Das Gupta, Kevin Schorno, Sumedha Gunewardena, Ari Melnick, Adrian Wiestner, Peng Huang, Rekha Rao, Lata Chauhan, John C. Byrd, Min Shen, Warren Fiskus, Kapil N. Bhalla, Nakhle S. Saba, Christopher P. Austin, Jinyun Liu
Publikováno v:
Cancer Research. 74:2520-2532
Chronic lymphocytic leukemia (CLL) exhibits high remission rates after initial chemoimmunotherapy, but with relapses with treatment, refractory disease is the most common outcome, especially in CLL with the deletion of chromosome 11q or 17p. In addre
Autor:
Alice C. Fan, Hua Fan-Minogue, Sanjiv S. Gambhir, Ramasamy Paulmurugan, Dean W. Felsher, Sandhya Bodapati, Tarik F. Massoud, David E. Solow-Cordero
Publikováno v:
Molecular Cancer Therapeutics. 12:1896-1905
Deregulation of c-Myc plays a central role in the tumorigenesis of many human cancers. Yet, the development of drugs regulating c-Myc activity has been challenging. To facilitate the identification of c-Myc inhibitors, we developed a molecular imagin
Autor:
Liqun Huang, Nengtai Ouyang, Basil Rigas, Gang Xie, Ka-Wing Cheng, Timothy S. Wiedmann, Ninche Alston, Gerardo G. Mackenzie, Chi Chun Wong
Publikováno v:
Molecular Cancer Therapeutics. 12:1417-1428
Phospho-sulindac is a sulindac derivative with promising anticancer activity in lung cancer, but its limited metabolic stability presents a major challenge for systemic therapy. We reasoned that inhalation delivery of phospho-sulindac might overcome
Autor:
Nan Liu, Yin Sun, Chaozhao Liang, Ryan K. Thor, Elaine Hsia, Robert Damoiseaux, Boxiao Ding, Sheng Tai, Sunita Bhuta, Jiaoti Huang
Publikováno v:
Molecular Cancer Therapeutics. 11:1320-1331
PI3K/AKT/mTOR pathway plays a key role in the tumorigenesis of many human cancers including prostate cancer. However, inhibitors of this pathway, such as Rad001, have not shown therapeutic efficacy as a single agent. Through a high-throughput screen
Autor:
Kieron Dunleavy, Wyndham H. Wilson, Delong Liu, Yihong Ye, Adrian Wiestner, Edgar G. Rizzatti, Nalini Raghavachari, Therese White, Megan M. Tweito, Qiuyan Wang, Peter J. Munson, Marc A. Weniger, Patricia Pérez-Galán
Publikováno v:
Clinical Cancer Research. 17:5101-5112
Purpose: Proteasome inhibition disrupts protein homeostasis and induces apoptosis. Up to 50% of patients with relapsed mantle cell lymphoma (MCL) respond to bortezomib. We used gene expression profiling to investigate the connection between proteasom
Autor:
John Lewicki, Austin L. Gurney, Min Wang, Timothy Hoey, Gilbert O'Young, Ann M. Kapoun, Marcus Fischer, Wan-Ching Yen
Publikováno v:
Cancer Research. 71:1520-1525
KRAS mutations are frequent in colorectal cancer (CRC) and are associated with clinical resistance to treatment with the epidermal growth factor receptor (EGFR)–targeted monoclonal antibodies. Delta-like 4 ligand (DLL4) is an important component of